213 related articles for article (PubMed ID: 15170731)
1. Enhancer-deleted retroviral vectors restore high levels of superoxide generation in a mouse model of CGD.
Schwickerath O; Brouns G; Thrasher A; Kinnon C; Roes J; Casimir C
J Gene Med; 2004 Jun; 6(6):603-15. PubMed ID: 15170731
[TBL] [Abstract][Full Text] [Related]
2. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
Sugimoto Y; Tsukahara S; Sato S; Suzuki M; Nunoi H; Malech HL; Gottesman MM; Tsuruo T
J Gene Med; 2003 May; 5(5):366-76. PubMed ID: 12731085
[TBL] [Abstract][Full Text] [Related]
3. Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches.
Brandtner EM; Kodajova P; Hlavaty J; Jandl G; Tabotta W; Salmons B; Günzburg WH; Hohenadl C
J Gene Med; 2008 Feb; 10(2):113-22. PubMed ID: 18076132
[TBL] [Abstract][Full Text] [Related]
4. Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells.
Moreno-Carranza B; Gentsch M; Stein S; Schambach A; Santilli G; Rudolf E; Ryser MF; Haria S; Thrasher AJ; Baum C; Brenner S; Grez M
Gene Ther; 2009 Jan; 16(1):111-8. PubMed ID: 18784749
[TBL] [Abstract][Full Text] [Related]
5. Chronic granulomatous disease: towards gene therapy.
Thrasher A; Segal A; Casimir C
Immunodeficiency; 1993; 4(1-4):327-33. PubMed ID: 8167728
[TBL] [Abstract][Full Text] [Related]
6. Functional reconstitution of oxidase activity in X-linked chronic granulomatous disease by retrovirus-mediated gene transfer.
Zentilin L; Tafuro S; Grassi G; Garcia R; Ventura A; Baralle F; Falaschi A; Giacca M
Exp Cell Res; 1996 Jun; 225(2):257-67. PubMed ID: 8660913
[TBL] [Abstract][Full Text] [Related]
7. Expression of human glucocerebrosidase in murine macrophages: identification of efficient retroviral vectors.
Freas-Lutz DL; Correll PH; Dougherty SF; Xu L; Pluznik DH; Karlsson S
Exp Hematol; 1994 Aug; 22(9):857-65. PubMed ID: 8062885
[TBL] [Abstract][Full Text] [Related]
8. Progress in gene therapy for chronic granulomatous disease.
Malech HL
J Infect Dis; 1999 Mar; 179 Suppl 2():S318-25. PubMed ID: 10081502
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for chronic granulomatous disease.
Kume A; Dinauer MC
J Lab Clin Med; 2000 Feb; 135(2):122-8. PubMed ID: 10695656
[TBL] [Abstract][Full Text] [Related]
10. Hybrid retroviral vector with MCK enhancers inserted in LTR for stable and specific expression of human factor IX in skeletal muscle.
Wang JM; Hou J; Qiu XF; Kurachi K; Xue JL
Chin Med J (Engl); 2004 Jun; 117(6):893-8. PubMed ID: 15198894
[TBL] [Abstract][Full Text] [Related]
11. Genetic reshuffling reconstitutes functional expression cassettes in retroviral vectors.
Tabotta W; Klein D; Hohenadl C; Salmons B; Günzburg WH
J Gene Med; 2001; 3(5):418-26. PubMed ID: 11601755
[TBL] [Abstract][Full Text] [Related]
12. Expansion of genetically corrected neutrophils in chronic granulomatous disease mice by cotransferring a therapeutic gene and a selective amplifier gene.
Hara T; Kume A; Hanazono Y; Mizukami H; Okada T; Tsurumi H; Moriwaki H; Ueda Y; Hasegawa M; Ozawa K
Gene Ther; 2004 Sep; 11(18):1370-7. PubMed ID: 15229634
[TBL] [Abstract][Full Text] [Related]
13. Progress toward effective gene therapy for chronic granulomatous disease.
Malech HL; Choi U; Brenner S
Jpn J Infect Dis; 2004 Oct; 57(5):S27-8. PubMed ID: 15507764
[TBL] [Abstract][Full Text] [Related]
14. Long-term high-level reconstitution of NADPH oxidase activity in murine X-linked chronic granulomatous disease using a bicistronic vector expressing gp91phox and a Delta LNGFR cell surface marker.
Sadat MA; Pech N; Saulnier S; Leroy BA; Hossle JP; Grez M; Dinauer MC
Hum Gene Ther; 2003 May; 14(7):651-66. PubMed ID: 12804147
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy of chronic granulomatous disease (CGD) by gene transfer into hematopoietic stem cells.
Zentilin L; Tafuro S; Serra C; Falaschi A; Giacca M
Ann Ist Super Sanita; 1998; 34(4):447-55. PubMed ID: 10234875
[TBL] [Abstract][Full Text] [Related]
16. Stable long-term gene correction with low-dose radiation conditioning in murine X-linked chronic granulomatous disease.
Goebel WS; Pech NK; Dinauer MC
Blood Cells Mol Dis; 2004; 33(3):365-71. PubMed ID: 15528159
[TBL] [Abstract][Full Text] [Related]
17. Development of an in vitro cell culture assay system for measuring the activation of a neighbouring gene by the retroviral vector.
Hong Y; Yu SS; Yoon NK; Kang SJ; Lee JT; Kim S; Kim JM; Lee K; Jang JW; Kim S
J Gene Med; 2008 Aug; 10(8):847-54. PubMed ID: 18563862
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate selectable retroviral vectors for Gaucher disease.
Havenga MJ; Werner AB; Valerio D; van Es HH
Gene Ther; 1998 Oct; 5(10):1379-88. PubMed ID: 9930344
[TBL] [Abstract][Full Text] [Related]
19. Use of the hereditary persistence of fetal hemoglobin 2 enhancer to increase the expression of oncoretrovirus vectors for human gamma-globin.
Fragkos M; Anagnou NP; Tubb J; Emery DW
Gene Ther; 2005 Nov; 12(21):1591-600. PubMed ID: 15944728
[TBL] [Abstract][Full Text] [Related]
20. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells.
Santilli G; Almarza E; Brendel C; Choi U; Beilin C; Blundell MP; Haria S; Parsley KL; Kinnon C; Malech HL; Bueren JA; Grez M; Thrasher AJ
Mol Ther; 2011 Jan; 19(1):122-32. PubMed ID: 20978475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
